As Cash Runs Out, Helicos's Future Remains Uncertain Beyond Year End | GenomeWeb

By Julia Karow

Faced with limited revenue, upcoming debt payments, and a dwindling amount of cash, Helicos BioSciences' outlook for 2012 remains bleak, despite the firm's recent cost-cutting measures.

Earlier this week, Helicos reported $725,000 in third-quarter revenue and a $798,000 net loss for the quarter. As of Nov. 1, it had $1.6 million in total available resources, including $275,000 in cash and equivalents and $1.33 million from a bridge debt financing facility it secured last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.